RTP-based BioMarck Pharmaceuticals (www.biomarck.com), a biopharmaceutical company, has been granted an intellectual patent from the U.S. Patent and Trademark Office for its proprietary technology of “methods and compositions for alternating mucus secretion.� The company is testing a treatment for respiratory diseases based on technology that it has licensed from North Carolina State. The treatment is designed to combat mucus.
BioMarck Pharmaceuticals is a CED member.